New organ coating could help prevent transplant rejection

It makes the immune system see the donated organ as a non-threat.

Organ transplant patients must take drugs that suppress their immune systems to avoid their body rejecting the new organ — a regimen that put them at risk from infections even before the pandemic.

Now, scientists have developed a coating for donated organs that minimizes the chance of transplant rejection. So far, it’s only been tested in mice, but it might one day eliminate the need for anti-rejection meds altogether.

Transplant rejection: The immune system’s primary job is to detect and attack foreign invaders in the body.

When those invaders are bacteria and viruses, this prevents us from getting sick, but unfortunately, the immune system sees transplanted organs as foreign and will attack them, too. 

About a third of organ transplants end in rejection.

This can lead to transplant rejection, so organ recipients have to take drugs (called immunosuppressants) that suppress their immune system — usually for the rest of their lives.

Why it matters: Immunosuppressants can cause serious side effects and increase the risk of infection.

The drugs aren’t guaranteed to prevent transplant rejection, too — about a third of organ transplants still end in rejection, landing patients right back on the waiting list for a new organ.

A different approach: Instead of weakening the immune system to prevent transplant rejection, researchers from the U.S. and Canada have developed a way to make donated organs fly under the radar.

“Blood vessels in our organs are protected with a coating of special types of sugars that suppress the immune system’s reaction,” researcher Jayachandran Kizhakkedathu from the University of British Columbia said in a press release

“[B]ut in the process of procuring organs for transplantation,” he continued, “these sugars are damaged and no longer able to transmit their message.” 

In other words, the organs become super visible to the immune system.

“We were amazed by the ability of this new technology to prevent rejection.”

Jonathan Choy

The researchers invented a synthetic polymer that could replace these sugars, as well as a process for applying it to blood vessels. When transplanted into mice, arteries and kidneys coated in their creation took to the new hosts just fine, even without immunosuppressive drugs. 

“We were amazed by the ability of this new technology to prevent rejection in our studies,” researcher Jonathan Choy from Simon Fraser University said. “To be honest, the level of protection was unexpected.”

The next steps: So far, the coating has only been tested in mice, and human trials may still be several years away, according to the researchers. 

However, they believe that their coating might be able to prevent transplant rejection in people receiving lungs, hearts, and other organs. If so, recipients might one day have a better shot of keeping their new organs forever without having to trade their immune system in the bargain.

We’d love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at [email protected].

Related
In a future with brain-computer interfaces like Elon Musk’s Neuralink, we may need to rethink freedom of thought
In a future with more “mind reading,” thanks to computer-brain interfaces, we may need to rethink freedom of thought.
Personalized cancer vaccines are having a moment
Personalized cancer vaccines were a recurring theme at the annual meeting of the American Association for Cancer Research in 2024.
When an antibiotic fails: MIT scientists are using AI to target “sleeper” bacteria
Most antibiotics target metabolically active bacteria, but AI can help efficiently screen compounds that are lethal to dormant microbes.
What’s next for COVID-19 drugs?
Paxlovid may have underperformed in a new trial, but other promising COVID-19 drugs are being authorized or in the works.
Old drug appears to halt progression of Parkinson’s motor symptoms
A GLP-1 agonist used to treat diabetes appeared to halt the progression of Parkinson’s symptoms in a phase 2 trial.
Up Next
Subscribe to Freethink for more great stories